Please login to the form below

Not currently logged in
Email:
Password:

Rajesh Chopra joins board of e-Therapeutics

VP of translational and early drug development at Celgene joins as e-Therapeutics prepares to advance several investigational drugs into clinical trials

Dr Rajesh Chopra is to join the board of e-Therapeutics as a non-executive director.

He serves as VP of translational and early drug development at Celgene and joins UK-based drug discovery and development company e-Therapeutics as it prepares to advance several investigational drugs into clinical trials.

Prior to his current role at Celgene, where he is leading efforts to integrate drug discovery and clinical development at Celgene sites in the US and Europe, Chopra spent five years at AstraZeneca (AZ).

During his time at AZ he eventually held the role of medical science director, senior principal scientist and disease area team leader for blood cancers.

Chopra has also held positions outside pharma, working as a clinician and academic in the UK, and spent seven years as clinical director of the Department of Haematological Oncology at the Christie Hospital in Manchester. He is also a a Fellow of both the Royal College of Physicians and the Royal College of Pathologists in the UK.

Professor Oliver James, chair of e-Therapeutics, said: “Rajesh's appointment represents a further significant strengthening of our Board. He brings highly relevant senior-level experience gained in world-leading pharma and biotech companies and substantial expertise in oncology.

“His input will be of great value as we advance our clinical programmes and bring more new drugs through into development from our discovery operation.”

7th February 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics